An Introduction to Dermatological Cancer
The past decade has seen significant advances in the treatment landscape of melanoma. Therapies targeting the BRAF oncoprotein pathway and the development of immunotherapies have transformed the standard of care for patients.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Dermatological Cancer Content
Recognizing mycosis fungoides, a heterogeneous and challenging cutaneous T-cell lymphoma
Watch this activity to learn more about mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and a new MF-CTCL online resource. Visit MF-Talks for more information.
Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma
touchREVIEWS in Oncology & Haematology. 2021;17(2):58–9 DOI: https://doi.org/10.17925/OHR.2021.17.2.58
RELATIVITY-047 reported on the initial efficacy and safety of relatlimab (RELA), an antibody to lymphocyte-activating gene 3 (LAG-3), in combination with nivolumab (NIVO), an antibody to programmed cell death 1 (PD-1).1 These positive findings add to the existing evidence for the efficacy of anti-PD-1 therapy – either alone or in combination with ipilimumab (IPI), an antibody […]
Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Questions 1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to […]
Evan Lipson, ASCO 2021: Relatlimab plus Nivolumab in Advanced Melanoma
TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma. The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III […]
Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study
Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study. Questions What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic […]
Ana Maria Arance Fernandez, ESMO 2020 – Lenvatinib plus Pembrolizumab for Advanced Melanoma: Initial Results of LEAP-004
touchONCOLOGY meets with Dr Ana Maria Arance Fernandez at ESMO 2020 to discuss findings from the LEAP-004 trial, and the role lenvatinib plus pembrolizumab can play in the treatment of advanced melanoma. The late-breaking abstract ‘Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of […]
BRAF-mutant Melanoma – The COLUMBUS Trial
European Oncology & Haematology. 2018;14(2):78–9 DOI: https://doi.org/10.17925/EOH.2018.14.2.78
Melanoma represents a significant and increasing public health burden, and is the largest cause of skin cancer-related deaths.1 Approximately half of advanced (unresectable or metastatic) melanomas have a mutation in the BRAF gene, with V600E being the most common mutation, leading to the therapeutic use of BRAF inhibitors.2 However, the response rates with single-agent BRAF […]
Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma. Questions: 1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European approval of encoranefib plus binimetanib for BRAF-mutant metastatic melanoma? (0:11) […]
Paolo A Ascierto, ESMO 2018 – Developments in the Treatment of Advanced Melanoma
touchONCOLOGY met with editorial board member Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this expert interview, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the last few years. However, the levels of toxicity […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!